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There are only a few studies with a small sample size of patients that have compared the risks of using chest tubes versus
thoracentesis in hepatic hydrothorax. It has been shown that many complications may arise secondary to chest tube
placement and is associated with increased morbidity and mortality. In this retrospective study, patients with cirrhosis
were identiﬁed from the 2009 National Inpatient Sample by using ICD-9 codes; we evaluated the risk of chest tube versus
thoracentesis in a largest population with hepatic hydrothorax to date to measure the mortality and the length of stay. A
total of 140,573 patients with liver cirrhosis were identiﬁed. Of this, 1981 patients had a hepatic hydrothorax and ended
up with either thoracentesis (1776) or chest tube (205). The mortality in those who received a chest tube was two times
higher than that in thoracentesis group with a P value of ≤0.001 (CI 1.43–312). In addition, the length of hospital stay of
the chest tube group was longer than that of the thoracentesis subset (7.2 days versus 3.8 days, resp.). We concluded that
chest tube placement has two times higher mortality rate and longer hospital length of stay when compared to patients
who underwent thoracentesis.
1. Introduction
Cirrhosis is the end stage of chronic liver disease, which
occurs due to gradual hepatic ﬁbrosis leading to the irrevers-
ible destruction of liver anatomy. Liver cirrhosis has a high
morbidity and mortality, which is the 14th most common
cause of death all over the world and the 4th in central
Europe. It leads to more than 1 million deaths per year in
the world, and greater than 150,000 deaths per year in
Europe [1]. The most common causes of liver cirrhosis are
alcohol, chronic viral infection (hepatitis B or C), and nonal-
coholic steatohepatitis (NASH) [2]. In early stages, the condi-
tion may be reversible by treating the underlying cause, but in
later stages, liver transplant will be the ultimate therapy [3].
Shortness of breath and hypoxia are very common in
patients with liver cirrhosis for a multitude of reasons
[4]. It can be due to the mechanical impingement of the
ascetic ﬂuid on the diaphragm, hepatopulmonary syn-
drome [5], portopulmonary hypertension [6], and cirrhotic
cardiomyopathy [7].
Hepatic hydrothorax is one of the complications of liver
cirrhosis, which may cause shortness of breath as well, occur-
ring in less than 10% of cirrhotic patients with known portal
hypertension [8]. The ascetic ﬂuid will spread into the chest
at the pleural cavity via a defect in the diaphragm and usually
accumulating in the pleural space of the right lung [9].
Patients are usually advised to limit the salt and ﬂuid
intake along with diuretic use [10, 11]. Some patient may
need thoracentesis [12], transjugular intrahepatic portosyste-
mic shunt placement [13], pleurodesis [14], thoracoscopic
surgery to repair diaphragmatic defects [15], or liver trans-
plantation [16]. The following article will discuss and review
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the risk of the complications of chest tubes compared with
thoracentesis in cirrhotic patients with hepatic hydrothorax.
2. Method
The 2009 National Inpatient Sample (NIS) was used to create
a panel of patients diagnosed with cirrhosis. The NIS is one of
the largest publicly available database that has more than 7
million admissions from nationally distributed all over the
united states including private, academic, nonfederal, and
public hospitals. The NIS is part of the Healthcare Cost and
Utilization Project (HCUP) by the Agency for Healthcare
Research and Quality (AHRQ). Data including age, sex, race,
length of stay, type of payers, admission types, primary and
secondary diagnosis, hospital cost, hospital types and loca-
tion, and other variables are included in the NIS.
2.1. Case and Outcome Variable Identiﬁcations. The ICD-9
(the clinical modiﬁcation of the International Classiﬁcation
of Diseases) diagnostic codes were used to identify patients
with history of liver cirrhosis (ICD-9= 5718). The following
ICD-9 codes were also used: chest tube placement (3404),
thoracentesis (3491), hydrothorax (5118), and transudate
pleural eﬀusion (5119). Other variables used in this study
have already been identiﬁed in the NIS data, for instance, race
and sex.
2.2. Statistical Analysis. The primary outcome of the study
was examining the safety and the mortality diﬀerence of chest
tube placement versus thoracentesis in people with cirrhosis
complicated by hepatic hydrothorax. We also assessed the
mortality diﬀerence of chest tube placement versus thora-
centesis in cirrhotic versus noncirrhotic patients. Data was
reviewed and analyzed using the IBM SPSS version 24 statis-
tical software for Mac computer. The target population ana-
lyzed was cirrhotic patients with hydrothorax or transudate
pleural eﬀusion-related admissions. The target population
was further subdivided into people who had chest tube
placement for drainage versus those who had thoracentesis.
Mean, percentages, and standard deviation of the mean were
used to examine the demographic feature of the target pop-
ulation. A multivariate logistic regression statistical test was
used to compare the mortality and morbidity diﬀerence
between these two groups. A conﬁdence interval (CI) of
95% and P value less than 0.05 were determined to deﬁne
the statistical diﬀerence between the two groups.
3. Result
A total of 140,573 patients with diagnosis of cirrhosis were
identiﬁed using ICD-9 code. Only 1981 patients out of
140,573 had transudate pleural eﬀusion or hydrothorax and
underwent a thoracentesis or chest tube during their hospi-
talization. 1776 had a thoracentesis (diagnosis and/or thera-
peutic) and 205 had a chest tube. 1121 (56.6%) were male
and 860 (43.4%) were female (Table 1). 1240 (69.6%) were
white, 154 (8.6%) black, 291 (16.3%) Hispanic, 48 (2.7%)
Asian, 10 (0.6%) Native American, and 39 (2.2%) others
(Table 2). Mean length of stay was 7.2± 15.5 for a patient
with chest tube and 3.8± 10 for a patient with thoracentesis.
Mean age was 60.38± 15 versus 60± 13.4 in people with chest
tube versus thoracentesis, respectively (Table 3). The inpa-
tient mortality was two times greater in the chest tube group
than in the thoracentesis group (odds ratio = 2.1; P value ≤
0.001, CI 1.43–312). In addition, the length of stay of the
chest tube group was longer than that of the thoracentesis
group (7.2 days versus 3.8 days, resp.) (Table 3). The mor-
tality was also 2 times higher in cirrhotic patients who had
chest tube comparing to noncirrhotic patients who had
chest tube (odds ratio = 2, P value ≤ 0.001, CI 1.39–2.9).
The mortality was 1.3 times higher in cirrhotic patients who
had thoracentesis compared to noncirrhotic patients with
thoracentesis (odds ratio 1.3, P value ≤ 0.01, CI 1.14–159).
Comparing male versus female, cirrhotic patients who
Table 1: Gender.
Chest tube Thoracentesis Total
ISEX
Male
Count 113 1008 1121
% 55.1% 56.8% 56.6%
Female
Count 92 768 860
% 44.9% 43.2% 43.4%
Total
Count 205 1776 1981
% 100.0% 100.0% 100.0%
Table 2: Race.
Chest tube Thoracentesis Total
Race (uniform)
White
Count 131 1109 1240
% 72.4% 69.3% 69.6%
Black
Count 15 139 154
% 8.3% 8.7% 8.6%
Hispanic
Count 30 261 291
% 16.6% 16.3% 16.3%
Asian
Count 2 46 48
% 1.1% 2.9% 2.7%
Native American
Count 1 9 10
% 0.6% 0.6% 0.6%
Others
Count 2 37 39
% 1.1% 2.3% 2.2%
Total
Count 181 1601 1782
% within 100.0% 100.0% 100.0%
Table 3: Length of stay.
Mean length
of stay
(days) S.E.
Mean Age S.E.
Chest tube in cirrhotic
patient
7.21 15.56 60.38 15.43
Thoracentesis in cirrhotic
patient
3.8 10.44 60.61 13.48
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had a chest tube and or/thoracentesis had no signiﬁcant
mortality diﬀerence (value = 0.731, odds ratio = 0.97, and
CI 0.71–1.21). Comparing white to black cirrhotic patients
who had a chest tube and/or thoracentesis also had no signif-
icant mortality diﬀerence (P value = 0.127, odds ratio = 1.6,
CI 0.8–3.1) (Table 4).
4. Discussion
Hepatic hydrothorax is a rare complication of liver cirrhosis.
Less than 10% of patients with severe liver disease may end
up with hepatic hydrothorax, which commonly presents as
shortness of breath, and low oxygen saturation and can be
complicated by underlying infection. The development of a
hydrothorax is most likely due to the spread of the ascetic
ﬂuid, accumulating from portal hypertension, into the pleu-
ral space due to small diaphragmatic defects [17]. Following
emergence of symptoms, usually a simple chest X-ray is usu-
ally suﬃcient to point towards the diagnosis. Ultimately, a
thoracentesis will be needed for a ﬂuid sample to demon-
strate a transudate ﬂuid, like the peritoneal ﬂuid with a
greater protein concentration as pleura has a higher capacity
for reabsorption for water than in the peritoneum [18].
Rarely, hydrothorax patients may end up with an acute
tension hydrothorax, which generally leads to an acute
change in respiratory status along with hypotension [19].
Another complication of hepatic hydrothorax is spontaneous
bacterial empyema, which can happen around two percent of
cirrhotic patients and can be seen in up to 16% when patients
develop a hepatic hydrothorax [20].
Once a hydrothorax is diagnosed, the ﬁrst line of therapy
includes salt restriction, ﬂuid restriction, and diuresis [21].
Generally, guidelines following failure of these options are
slightly more ambiguous. When shortness of breath pro-
gresses to hypoxia due to the accumulation of hydrothorax,
a thoracentesis is a fast and useful tool for relieving the
symptom [22]. A patient who continues to decompensate
following the interventions should be assessed for liver
transplantation to reduce the risks of complications. Treat-
ment options for recurrent hepatic hydrothorax that are
not candidates for transplant include TIPS, repeated thor-
acentesis, and pleurodesis [23].
Multiple small-power studies have discussed the compli-
cations of chest tube placement for hepatic hydrothorax such
as subcutaneous emphysema, organ puncture, haemothorax
due to artery laceration, pulmonary edema from rapid
removal of ﬂuid (reexpansion pulmonary edema), misplace-
ment of chest tube, protein and electrolyte depletion, infec-
tion, bleeding, and death [8, 24–26].
In 2016, Sharaf-Eldin et al. devised a new technique by
using a pigtail catheter with a small caliber (22 gauge) for
treating recurrent hepatic hydrothorax and, also, concluded
that chest tube insertion for hepatic hydrothorax is associ-
ated with high complication rate and should be avoided [26].
One major ﬂaw with these prior studies is the small
sample used for most them. Our study contains the largest
sample size analyzed for complications and mortality of chest
tubes in patients with hepatic hydrothorax. We demonstrate
a clear increase in mortality as well as hospital length of stay
in patients who received a chest tube compared to those who
are managed with a thoracentesis (diagnostic or therapeutic).
We hope that by presenting this data, we can reiterate the
increased morbidity and mortality using chest tubes for
hepatic hydrothorax. We advocate for the use of repeated
thoracentesis, TIPS, and, if feasible, liver transplant as the
only therapeutic options for this condition.
Our study had several limitations that are inherent in the
use of an electronic administrative database (NIS), which
lacks the details available in standardized clinical trials.
Long-term outcomes, complications, indications, severity of
cirrhosis (MELD or Child-Pugh Score), and rehospitalization
rates could not be assessed using the NIS database. The out-
come of the procedure, degree of procedural diﬃculties, and
provider experience could not be assessed.
5. Conclusion
Chest tube placement for hepatic hydrothorax has two times
higher mortality and longer length of stay compared to those
who underwent thoracentesis.
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